Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (51-60 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Global patient safety and antiretroviral drug-drug interactions in the resource-limited settingKay Seden, Saye H Khoo, David Back, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugsJosé Moltó, Rajith Rajoli, David Back, et al.
The Journal of Infectious Diseases|December 20, 2018
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingRajith K R Rajoli, Paul Curley, Justin Chiong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
British Journal of Clinical Pharmacology|May 9, 2020
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactionsDavid Back, Catia Marzolini, Catherine Hodge, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
Antiviral Therapy|March 26, 2004
Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patientsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
HIV Clinical Trials|December 1, 2017
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individualsAkil Jackson, Laura Else, Christopher Higgs, et al.
Antiviral Therapy|January 18, 2005
Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parametersBridget Maher, Judy Lloyd, Edmund G L Wilkins, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Pageof 15

Showing results (51-60 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Global patient safety and antiretroviral drug-drug interactions in the resource-limited settingKay Seden, Saye H Khoo, David Back, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugsJosé Moltó, Rajith Rajoli, David Back, et al.
The Journal of Infectious Diseases|December 20, 2018
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingRajith K R Rajoli, Paul Curley, Justin Chiong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 27, 2012
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategiesAlessandro Schipani, Laura Dickinson, Marta Boffito, et al.
British Journal of Clinical Pharmacology|May 9, 2020
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactionsDavid Back, Catia Marzolini, Catherine Hodge, et al.
Clinical Pharmacokinetics|March 13, 2013
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approachMarco Siccardi, Catia Marzolini, Kay Seden, et al.
Antiviral Therapy|March 26, 2004
Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patientsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
HIV Clinical Trials|December 1, 2017
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individualsAkil Jackson, Laura Else, Christopher Higgs, et al.
Antiviral Therapy|January 18, 2005
Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parametersBridget Maher, Judy Lloyd, Edmund G L Wilkins, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Pageof 15